Search - tctmd.com

Displaying 281 - 300 of 400

Sort: Relevancy | Date

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Atrial Fibrillation

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation ESC 2016

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Presenter: Andreas Goette

August 30, 2016

Presentation

Outcomes of Patients With Atrial Fibrillation Undergoing PCI

Presenter: NR. Sutton

August 24, 2016

Presentation TVT 2016

Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes

Presenter: Fabian Nietlispach

June 17, 2016

Presentation TVT 2016

Complexities of Managing AS Patients With Atrial Fibrillation After TAVR

Presenter: Samir R. Kapadia

June 17, 2016

Presentation TVT 2016

Incidence and Clinical Impact of Atrial Fibrillation in TAVR Patients

Presenter: Philippe Généreux

June 16, 2016

Presentation EuroPCR 2016

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Presenter: Jens Erik Nielsen-Kudsk

May 20, 2016

Presentation TCT 2015

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Presenter: Isaac George, Augusto D. Pichard, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

Miscellaneous Emerging Technologies 4: Stent-Based Pulmonary Vein Isolation Approach to Atrial Fibrillation

Presenter: Greg L. Kaluza, Joachim Schofer, Glenn Van Langenhove

October 15, 2015

Presentation TCT 2015

Putting It All Together: How to Manage the Patient With Atrial Fibrillation Undergoing PCI

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

Considerations Regarding Renal Function in the Patient With Atrial Fibrillation

Presenter: Gerhard C. Schuler, C. Michael Gibson

October 14, 2015

Presentation TCT 2015

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Presenter: Gerhard C. Schuler, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Advertisement

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Atrial Fibrillation: Scope of the Problem

TAVR in Patients With Atrial Fibrillation

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Outcomes of Patients With Atrial Fibrillation Undergoing PCI

Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes

Complexities of Managing AS Patients With Atrial Fibrillation After TAVR

Incidence and Clinical Impact of Atrial Fibrillation in TAVR Patients

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Miscellaneous Emerging Technologies 4: Stent-Based Pulmonary Vein Isolation Approach to Atrial Fibrillation

Putting It All Together: How to Manage the Patient With Atrial Fibrillation Undergoing PCI

Considerations Regarding Renal Function in the Patient With Atrial Fibrillation

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content